Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Essex Bio-TechnologyHKSE:01061 +0.88%86 ROA % is 6.23% as of Jun. 2026, which is 47% below its 10-year median of 11.83. GuruFocus rates HKSE:01061 with a GF Score™ of 86/100 and a GF Value™ of HK$3.13 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 1,007 Drug Manufacturers companies, Essex Bio-Technology ranks better than 73.39% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Essex Bio-Technology's annualizedNet Income for the quarter that ended in Jun. 2026 was HK$221 Mil.
Essex Bio-Technology's average Total Assets over the quarter that ended in Jun. 2026 was HK$3,553 Mil. Therefore, Essex Bio-Technology's annualized ROA % for the quarter that ended in Jun. 2026 was 6.23%.
The historical rank and industry rank for Essex Bio-Technology's ROA % or its related term are showing as below:
HKSE:01061'
s ROA % Range Over the Past 10 Years
Min: 7.7 Med: 11.83 Max: 17.71
Current: 7.7
During the past 13 years, Essex Bio-Technology's highest ROA % was 17.71%. The lowest was 7.70%. And the median was 11.83%.
HKSE:01061's ROA % is ranked better than 73.39% of 1007
companies
in the Drug Manufacturers industry
Industry Median: 2.56
vs HKSE:01061: 7.70
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is two times the semi-annual (Jun. 2026) net income data. The Revenue data used here is two times the semi-annual (Jun. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Essex Bio-Technology's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Essex Bio-Technology ROA % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Essex Bio-Technology's ROA % distribution charts can be found below:
* The bar in red indicates where Essex Bio-Technology's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Jun. 2026) net income data.
ROA % is displayed in the 30-year financial page.
Essex Bio-Technology (HKSE:01061) has a ROA % of 6.23% as of Jun. 2026. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Essex Bio-Technology and its competitors. This is 47% below median its historical median of 11.83. Over the past decade, Essex Bio-Technology's ROA % has ranged from 7.70 to 17.71. According to the industry distribution chart, Essex Bio-Technology ranks #268 out of 1007 companies in the Drug Manufacturers industry, placing it in the top 26.6%.
Is Essex Bio-Technology's ROA % too high?
Essex Bio-Technology's current ROA % of 6.23% is 47% below median its 10-year median of 11.83. Over the past 10 years, this metric has ranged from a low of 7.70 to a high of 17.71. The Drug Manufacturers industry median ROA % is 2.56. Essex Bio-Technology's value of 6.23% is 143.4% above this industry median. Based on the distribution chart, Essex Bio-Technology ranks #268 out of 1007 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Essex Bio-Technology has a GF Score™ of 86/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Essex Bio-Technology's ROA % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Essex Bio-Technology ranks #268 out of 1007 companies for ROA %. This puts Essex Bio-Technology in the upper half of its industry. The industry median ROA % is 2.56. Essex Bio-Technology's value of 6.23% is 143.4% above this benchmark. Historically, Essex Bio-Technology's own ROA % has ranged from 7.70 to 17.71 over the past decade. While the company's 10-year median is 11.83 vs. the industry median of 2.56, Essex Bio-Technology has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Drug Manufacturers company?
The median ROA % among Drug Manufacturers companies is 2.56, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Essex Bio-Technology's current ROA % of 6.23% is 143.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Essex Bio-Technology and its competitors. For the Drug Manufacturers industry, the median ROA % is 2.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Essex Bio-Technology's current ROA % is 6.23%, which is 47% below median its own 10-year median of 11.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Essex Bio-Technology stock overvalued right now?
Based on GuruFocus' analysis, Essex Bio-Technology (HKSE:01061) is currently considered Modestly Undervalued. The stock's GF Value™ is HK$3.13, compared to a current price of HK$2.29 — trading 26.8% below its estimated fair value. The current ROA % is 6.23%, which is 47% below median its 10-year median of 11.83 and 143.4% above the Drug Manufacturers industry median of 2.56. Essex Bio-Technology's overall GF Score™ is 86/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Essex Bio-Technology (HKSE:01061), the current ROA % is 6.23% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Essex Bio-Technology (HKSE:01061) Overvalued in 2026?
Based on GuruFocus' analysis, Essex Bio-Technology stock appears to be undervalued.
The current stock price of HK$2.29 is trading 26.8% below its estimated GF Value™ of HK$3.13.
GuruFocus considers Essex Bio-Technology to be Modestly Undervalued.
Key valuation signals for HKSE:01061:
ROA %: 6.23% (47% below median its 10-year median of 11.83)
GF Value™: HK$3.13 vs. price of HK$2.29 (26.8% below fair value)
Industry Position: 143.4% above the Drug Manufacturers median (#268 of 1007)
No single metric tells the full story. See the HKSE:01061 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Essex Bio-Technology Ltd is principally engaged in investment holding and development, manufacture, and sale of biologic drugs in the People's Republic of China. The company is made up of segments of Ophthalmology products and Surgical products. Its products under Ophthalmology include the Beifushu series, Tobramycin Eye Drops, Levofloxacin Eye Drops, and Sodium Hyaluronate Eye Drops. The products under Surgical include the Beifuji series, Carisolv dental caries removal gel, and mouthwash. The majority of the group's revenue comes from the PRC, also operates in Hong Kong and other countries.
86GF Score
Get the complete analysis for HKSE:01061
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:01061 has been successfully added to your 
